Cipher Pharmaceuticals Inc
TSX:CPH
Gross Margin
Cipher Pharmaceuticals Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
364.3m CAD |
72%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
663.9B USD |
83%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
424.9B USD |
68%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
203.6B CHF |
74%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
179.8B GBP |
82%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
192.2B CHF |
76%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
84%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
211.9B USD |
78%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.9B USD |
74%
|
Cipher Pharmaceuticals Inc
Glance View
Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Cipher Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 72%.
You don't have any saved screeners yet